VIS vs XBI
Vanguard Industrials ETF vs SPDR S&P Biotech ETF
- • VIS has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VIS pays a higher dividend yield (0.89%).
Side-by-side metrics
| Metric | VIS | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.89% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $8.31B | $8.30B |
YTD return | 16.04% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.23 | 1.09 |
P/E ratio | 30.93 | — |
Last price | $339.77 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VIS top holdings
| CAT | Caterpillar Inc | 5.09% |
| GE | GE Aerospace | 4.59% |
| RTX | RTX Corp | 3.97% |
| GEV | GE Vernova Inc | 3.64% |
| BA | Boeing Co | 2.39% |
| DE | Deere & Co | 2.22% |
| HON | Honeywell International Inc | 2.20% |
| UBER | Uber Technologies Inc | 2.18% |
| ETN | Eaton Corp PLC | 2.13% |
| LMT | Lockheed Martin Corp | 1.93% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VIS
VIS (Vanguard Industrials ETF) is US industrials sector stocks. Managed by Vanguard, the fund carries $8.3B in assets under management, an expense ratio of 0.09%, a dividend yield of 0.89%. Its largest holding is Caterpillar Inc (CAT), which represents 5.1% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 0.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.